R&D Strategies of Pharmaceutical Companies and Current Status of CRO/SMO 2023
Language:
Japanese
Product Code No:
C65115200
Issued In:
2023/09
#of Pages:
164
Publication Cycle:
Format:
PDF
Geographic Coverage:
,
Japan
,
Industry:
Coverage: (Product/service)
R&D Strategies of Pharmaceutical Companies
Research Target:
Pharmaceutical Companies
Research Content:
- Major pharmaceutical companies focus on M&A and alliances to expand domain
- R&D strategies of major pharmaceutical companies: mid-term business plans, R&D fields and areas of central focus, R&D structure, joint development status, etc.
- CRO market is estimated to reach 260 billion yen and SMO market around 40 billion yen
TOC:
I. R&D Strategies of Pharmaceuticals and Actual Status & Perspective of CRO/SMO
1. R&D Strategies of Pharmaceuticals
2. Actual Status & Perspective of CRO
3. Actual Status & Perspective of SMO
II. R&D Strategies of Leading Pharmaceuticals
1. Astellas Pharma Inc.
2. AstraZeneca K.K.
3. Eisai Co., Ltd.
4. Otsuka Holdings Co., Ltd.
5. ONO PHARMACEUTICAL CO., LTD.
6. Kyowa Kirin Co., Ltd.
7. Sanofi K.K.
8. SHIONOGI & CO., LTD.
9. Sumitomo Pharma Co., Ltd.
10. DAIICHI SANKYO COMPANY, LIMITED
11. Takeda Pharmaceutical Company Limited.
12. Mitsubishi Tanabe Pharma Corporation
13. CHUGAI PHARMACEUTICAL CO., LTD.
14. Eli Lilly Japan K.K.
15. Novartis Pharma K.K.
16. Bayer Yakuhin, Ltd.
III. Strategies of CRO Companies and SMO Companies
1. EPS Holdings, Inc.
2. M3, Inc.
3. CMIC HOLDINGS Co., Ltd.
Plus, brief profiles of leading CROs (29 enterprises) and leading SMOs (21 enterprises)